Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05047094 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title revisedv9
  2. 2 versions Re-verified since Nov 19, 2024, no change to tracked fieldsv7-v8
  3. Site details revised at 1 of 3 sitesv6
  4. Study sites: 1 to 3v5
  5. Primary completion date: Dec 2025 to Dec 2026
    • Study completion date: Jun 2026 to Jun 2027
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date changed from estimate of Oct 2021 to Nov 2, 2021v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
Trial Details
NCT Number NCT05047094
Lead Sponsor Alpha Tau Medical LTD.
Conditions
(from sponsor)		 Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
Related terms Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms, Squamous Cell Carcinoma of Head and Neck
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov